Navigation Links
Cardiometabolic Health Congress Expert Faculty Weigh in on FDA Advisory Panel Recommendation for Novel Weight-Loss Medication
Date:2/28/2012

BOSTON, Feb. 28, 2012 /PRNewswire/ -- The Food and Drug Administration advisory panel voted on Wednesday, Feb. 22, 2012, in favor of recommending that the FDA approve the prescription obesity drug Qnexa.  If approved, this will be the first time in more than a decade that a prescription weight-loss medication receives FDA approval.  This landmark recommendation prompted the 2012 Cardiometabolic Health Congress (CMHC) expert faculty to weigh in on the implications of the potential approval of this novel obesity medication.

"I am pleased that the FDA advisory panel has been able to see a way forward to support therapies that will help patients and clinicians confront the obesity epidemic. While pharmacotherapy is not appropriate for everyone, it is important to have options to help patients," said Richard Pratley, MD, professor of medicine and director of the Diabetes and Metabolism Translational Medicine Unit at the University of Vermont College of Medicine in Burlington, VT.

Robert H. Eckel, MD, co-chair of the 2012 CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus, said, "I think the decision was a good one and is important for the academic and medical educational missions related to obesity and cardiovascular disease." 

"It is a very interesting development and a bit surprising," said Deepak L. Bhatt, MD, Chief of Cardiology, VA Boston Healthcare System, associate professor of medicine at Harvard Medical School, and senior investigator, TIMI Study Group.  He added, "I still think that a large study evaluating cardiovascular safety is needed."

The Chief Scientific Officer for the Association of Black Cardiologists and professor of clinical medicine at Tulane University School of Medicine, Keith C. Ferdinand, MD, cautioned that, "The fight against obesity needs to be multifactorial, including new medications. As a cardiologist, however, I consider it paramount that all clinicians remember to monitor our patients closely for cardiac risks, including heart rate and blood pressure, and not just treat obesity as a cosmetic concern."

Harold Bays, MD, medical director and president, Louisville Metabolic and Atherosclerosis Research Center, Inc., stated, "This [FDA advisory panel] decision validates the emerging recognition that adiposity, or fat weight gain, creates adipose tissue dysfunction or 'sick fat' which directly and indirectly contributes to metabolic disease.  As importantly, the Qnexa development program objectively supports how fat weight reduction improves adipose tissue function, effectively treats the metabolic and immune abnormalities of 'sick fat,' and thus improves the most common metabolic diseases encountered in clinical practice, such as elevated glucose, blood pressure, and dyslipidemia - all major cardiovascular disease risk factors."

The Centers for Disease Control and Prevention state that over 35 percent of American adults are obese, with 5 percent being considered morbidly obese. In addition, 33 percent of American adults are overweight.  In response to this obesity epidemic, the CMHC, the most influential U.S.-based medical and scientific conference in its field, gathers over 50 world-renowned experts in cardiometabolic health each year to educate clinicians on current strategies for the prevention, diagnosis and management of obesity, type 2 diabetes, atherosclerosis, hypertension, dyslipidemia, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.

"It is striking that the CMHC has become the undisputed leader in conferences that address the most important metabolic derangements of our time, due largely to the strength of the faculty and their interactions with an engaged audience," said James Gavin III, MD, PhD, CEO and Chief Medical Officer of Healing Our Village, Inc., and clinical professor of medicine, Emory University School of Medicine.

The 7th Annual CMHC will convene Oct. 10-13, 2012 in Boston, MA; it is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP.

For more information, contact Dina Kouveliotes at dk@cardiometabolichealth.org or 877.571.4700 or visit www.cardiometabolichealth.org


'/>"/>
SOURCE Cardiometabolic Health Congress
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
4. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Tone Deafness Explained, from the Harvard Health Letter
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
9. ViroPharma to Present at Three Upcoming Healthcare Conferences
10. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):